This discrepancy seems surprising at first, since evaluation of uPA/PAI-1 in the tumor tissue has been best established in patients with hormone receptor positive HER2-negative disease and the current ASCO clinical practice guideline discourages from its use in HER2-positive and triple-negative disease5. This evidence concerns the gene PLAU and neoplasm.